Driven by pressure to conduct trials more quickly and at reduced
cost, biopharmaceutical companies are focusing on recruitment as a
critical area. The Enrollment Insights Study provides in-depth
analysis of enrollment performance and practices. It not only
reports on essential performance indicators, but on the ways
companies execute strategy. Gain insight into why some companies
achieve better performance than others, and how your company can
accelerate its patient recruitment.
Among the performance indicators to be assessed are screen failure
rates, drop-out rates, randomization rates, recruitment cycle time,
and site initiation cycle times. The study undertakes a detailed
review of recruitment, including how performance varies by disease,
and couples that performance with region/country. Understand, too,
the level of recruitment taking place outside North America and
Western Europe and whether entry into emerging markets has had
significant effect on a given company’s ability to accelerate
recruitment. Explore relationships between the overall trial and
its sites and how these relationships alter a trial’s success.
Use results from this study to assess enrollment performance and
gain insight into the key factors and types of decisions that most
influence any given trial’s success.